|
|
||||||||||
|
J Am Coll Cardiol, 2006; 47:547-551, doi:10.1016/j.jacc.2005.09.031
(Published online 13 January 2006). © 2006 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||








* Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida
Lankenau Hospital, Wynnewood, Pennsylvania
Abbott, Abbott Park, Illinois
University of Munster School of Medicine, Bielefeld, Germany
|| University of Nancy, Vandoeuvre-les-Nancy, France
¶ Department of Medicine, University of Milano-Bicocca, Milano, Italy
# Hospital Clinic, Barcelona, Spain
** Instituto Cardiovascular de Guadalajara, Guadalajara, Mexico

University of Oxford, Oxford, United Kingdom

Prioario Division of Cardiology, Policlinico San Matteo, Pavia, Italy.
Manuscript received May 28, 2004; revised manuscript received September 2, 2005, accepted September 12, 2005.
* Reprint requests and correspondence: Dr. Carl J. Pepine, Division of Cardiovascular Medicine, University of Florida, 1600 SW Archer Road, Gainesville, Florida 32610-0277. (Email: pepincj{at}medicine.ufl.edu).
OBJECTIVES: We sought to determine predictors for adverse outcomes in hypertensive patients with coronary artery disease (CAD).
BACKGROUND: Factors leading to adverse outcomes in hypertensive patients with CAD are poorly understood. The INternational VErapamil-trandolapril STudy (INVEST) compared outcomes in hypertensive patients with CAD that were assigned randomly to either a verapamil sustained-release (SR)- or an atenolol-based strategy for blood pressure (BP) control. Trandolapril and hydrochlorothiazide were used as added agents. During follow-up (61,835 patient-years), BP control and the primary outcome (death, nonfatal myocardial infarction, and nonfatal stroke) were not different between strategies.
METHODS: We investigated risk for adverse outcome associated with baseline factors, follow-up BP, and drug treatments using Cox modeling.
RESULTS: Previous heart failure (adjusted hazard ratio [HR] 1.96), as well as diabetes (HR 1.77), increased age (HR 1.63), U.S. residency (HR 1.61), renal impairment (HR 1.50), stroke/transient ischemic attack (HR 1.43), smoking (HR 1.41), myocardial infarction (HR 1.34), peripheral vascular disease (HR 1.27), and revascularization (HR 1.15) predicted increased risk. Follow-up systolic BP <140 mm Hg or diastolic BP <90 mm Hg (HRs 0.82 or 0.70, respectively) and trandolapril with verapamil SR (HRs 0.78 and 0.79) were associated with reduced risk.
CONCLUSIONS: In hypertensive patients with CAD, increased risk for adverse outcomes was associated with conditions related to the severity of CAD and diminished left ventricular function. Lower follow-up BP and addition of trandolapril to verapamil SR each were associated with reduced risk.
| |||||||||||||
This article has been cited by other articles:
![]() |
P. M. Ho, D. J. Magid, S. M. Shetterly, K. L. Olson, P. N. Peterson, F. A. Masoudi, and J. S. Rumsfeld Importance of Therapy Intensification and Medication Nonadherence for Blood Pressure Control in Patients With Coronary Disease Arch Intern Med, February 11, 2008; 168(3): 271 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Mancia, F. Messerli, G. Bakris, Q. Zhou, A. Champion, and C. J. Pepine Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study Hypertension, August 1, 2007; 50(2): 299 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Sica Hypertension Treatment: How Important Is Consistency of Effect? Hypertension, August 1, 2007; 50(2): 287 - 288. [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |